Methofill

Methotrexate, the active ingredient in Methofill, is a Antimetabolite (Folate antagonist) presented as a subcutaneous injection for Subcutaneous use. It is used to manage rheumatoid arthritis, severe psoriasis, certain leukemias and lymphomas, and ectopic pregnancy.

GNH USA supplies Methofill as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methofill (methotrexate) acts as a folate antagonist to modify disease processes in several immune‑mediated and malignant conditions. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and improves plaque lesions. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: impedes tumor growth and induces cancer cell death. - Ectopic pregnancy: halts trophoblastic tissue development to allow medical resolution.

Methofill may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration (mouth sores). - Transient elevation of liver enzymes. - Decreased white blood cell count. - Alopecia (hair thinning).

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone marrow suppression. - Acute renal failure. - Severe infection due to immunosuppression. - Anaphylactic or severe hypersensitivity reactions.

Methofill requires careful monitoring and specific safety measures before and during therapy. - Pregnancy: contraindicated; teratogenic risk requires effective contraception. - Liver function: monitor transaminases regularly; avoid in severe hepatic disease. - Hematology: perform complete blood counts frequently; discontinue if severe cytopenia occurs. - Renal function: adjust or avoid in significant renal impairment. - Infection: postpone dosing during active infections and avoid live vaccines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity and myelosuppression. - Penicillins and other bactericidal antibiotics: may potentiate bone‑marrow suppression. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Proton‑pump inhibitors: may affect renal clearance. - Diuretics: can exacerbate nephrotoxicity. - Oral contraceptives: reduced effectiveness; supplemental contraception advised. - Other folate antagonists (e.g., trimethoprim): additive hematologic toxicity.